Nociception Level Index as Monitorization of Pain at the Intensive Care

Sponsor
Haseki Training and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05762666
Collaborator
(none)
60
1
2
4.9
12.3

Study Details

Study Description

Brief Summary

The aim of our study is to evaluate the effectiveness of a nociception monitor in providing adequate postoperative analgesia for patients needing critical care after surgery. Besides, the study searches to determine the difference between the amount of analgesic medication used when guided by nociception or standard pain management protocols. It is also aimed to reveal the incidence of delirium when pain management is managed under the nociception level index (NOL) guidance.

60 postoperative patients admitted to the postanesthesia care unit (PACU) after general anesthesia for surgery for more than 2 hours will be included and allocated into 2 groups(n=30): the control group (Group A) and the study group (Group B). Group Standard of care will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them. However, Group NOL will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales. Data to be recorded are total postoperative analgesic consumption, NOL values along with CPOT scores, and delirium.

Condition or Disease Intervention/Treatment Phase
  • Device: nociception level index monitor
N/A

Detailed Description

the investigators designed a prospective study after approval of our Institutional ethics committee (dossier no:212-2022) and planned to allocate 60 patients (2 groups; 1:1 allocation; n=30). This study is designed under the Declaration of Helsinki and written informed consent will be obtained before surgery. Patients within the study should have general anesthesia for surgery for more than 2 hours and also planned for follow-up at the postanesthesia care unit (PACU). Among these, an investigator selects patients aged over 18 and having American society of anesthesiology (ASA) scores I-III. Exclusion criteria are refusal to participate in the study; patients with additional organ failure especially lung failure (Pao2/fio2 value below 200); history of allergies to drugs used in the study protocol; patients receiving deep anesthesia with sedation infusion RASS -2 (unable to be awakened by uncooperative audible stimulus); patients with head trauma expected to have a low postoperative Glasgow coma score (GCS); the presence of surgical complication, arrhythmia, and sepsis during the hospital stay.

Randomization is designed with concealed opaque envelope in a 1:1 ratio into 2 groups (n= 30): the control group (Group Standard of care) and the study group (Group NOL). When the inclusion/exclusion criteria are met, on the day of the surgery the anesthetist in the operating room will choose one envelope to apply the designed protocol for each group. Data obtained at the clinical follow-up will be gathered by informed nurses at the ICU. All evaluations at the surgical wards especially for delirium and cognitive dysfunction will be evaluated by the same independent anesthetist who is blind to the study groups.

All patients will receive standard analgesia protocol as 1 gr paracetamol (maximum dose 4x1 and minimum dose interval as 6 hours) and rescue analgesia as 1mg/kg tramadol (maximum dose 4x1 and minimum dose interval as 6 hours). Moreover, if analgesia is not ensured 0,05 mg/kg morphine (IV) bolus doses are planned when their pain scales or NOL values are high (NRS >4; CPOT>2; NOL >25 over 1 minute). NRS and CPOT will be used as pain scales at postoperative 6th, 8th, 12th, and 24th hours for all patients. The Group Standard will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them. However, Group NOL will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales. The total amount of analgesics used during the ICU stay will be noted. Delirium and cognitive dysfunction will be evaluated at the 24th hour before discharge by CAM-ICU score and by 4AT at the surgical ward on the postoperative 3rd day before hospital discharge.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Group A will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them. However, Group B will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales.Group A will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them. However, Group B will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales.
Masking:
Double (Care Provider, Outcomes Assessor)
Masking Description:
Data obtained at the clinical follow-up will be gathered by care provider nurses at the ICU who are blind to the study protocol. All evaluations at the surgical wards especially for delirium and cognitive dysfunction will be evaluated by the same independent anesthetist who is blind to the study groups.
Primary Purpose:
Supportive Care
Official Title:
Pain Monitoring in Intensive Care: How the Use of Nociception Level Index Affects Treatment and Prognosis?
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Group Standart of care

Patients will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them

Experimental: Group Nociception level index monitor

Patients will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales

Device: nociception level index monitor
The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)

Outcome Measures

Primary Outcome Measures

  1. critical care observation pain tool [postoperative 24 hour]

    critical care observation pain tool (CPOT) behavioral pain assessment score over 2 is accepted as pain to apply analgesia

  2. number rating scale(NRS) [postoperative 24 hour]

    number rating scale(NRS) value over 4 is accepted as pain to apply analgesia

Secondary Outcome Measures

  1. The total amount of analgesic drug [postoperative 24 hour]

    morphine and tramadol used at postoperative follow-up

  2. Delirium [postoperative 24th hour]

    Confusion Assessment Method for the ICU (CAM-ICU) at 24th hour : outcome will be decided as positive or negative after interrogation of course of mental status, consciousness, inattention and disorganized thinking

  3. cognitive dysfunction [postoperative 24th hour and postoperative 3th day]

    Arousal, Attention, Abbreviated Mental Test (4AT) scores at 24th hour and postoperative 3th day: A score of 1-3 suggests cognitive impairment and a score of 4 or more suggests delirium

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists (ASA) Physical Status classification I to III

  • Patients who have been admitted to the postoperative intensive care unit

  • Patients necessitating general anesthesia for surgery of more than 2 hours

  • Patients who need mechanical ventilation for a while in intensive care follow-up

Exclusion Criteria:
  • Patients with additional organ failure

  • Disease that may make it difficult to wean from the ventilator when lung functions are evaluated (Pao2/fio2 value below 200)

  • History of allergies to drugs used in the study protocol

  • Patients receiving deep anesthesia with sedation infusion RASS -2 (unable to be awakened by uncooperative audible stimulus)

  • Patients with head trauma expected to have a low postoperative Glasgow coma score

  • Presence of arrhythmia

  • Presence of sepsis during the hospital stay

  • Patients who stay more than 48 hours at the postoperative intensive care unit

  • Presence of surgical complication

  • Known hepatic insufficiency or decreased function

  • Known renal insufficiency or decreased function

Contacts and Locations

Locations

Site City State Country Postal Code
1 Haseki Training and Research Hospital Istanbul Sultangazi Turkey 34000

Sponsors and Collaborators

  • Haseki Training and Research Hospital

Investigators

  • Principal Investigator: Berna Caliskan, MD, Haseki Training and Research Hospital Anesthesiology and Reanimation Department

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Haseki Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT05762666
Other Study ID Numbers:
  • 212-2022
First Posted:
Mar 9, 2023
Last Update Posted:
Mar 9, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Haseki Training and Research Hospital

Study Results

No Results Posted as of Mar 9, 2023